Key result
Dapagliflozin correction notice provides no clinical results regarding cardiorespiratory fitness post-PCI.
Answers are grounded in this paper and cite their sources.
Dapagliflozin may improve post-PCI exercise capacity in T2DM/CHD; extends SGLT2i evidence to CRF endpoints in this population.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question. Dapagliflozin's effect on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes following PCI was addressed in a correction notice lacking specific clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: